Zonisamide

Generic Name: Zonisamide

Brand Names: Zonegran, Zonisade, Zonisamide Mylan

Drug Type: Small Molecule

Chemical Formula: C_₈H_₈N_₂O_₃S

CAS Number: 68291-97-4

Unique Ingredient Identifier: 459384H98V

Background: Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate. Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.

Indication: Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Zonisamide oral suspension is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.

Associated Conditions: Partial-Onset Seizures

Associated Therapies: -

Clinical Trials

ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs

Phase 4

Completed

Conditions: Epilepsy

Interventions: Drug: Zonisamide

First Posted Date: 2008-04-17

Last Posted Date: 2013-05-13

Lead Sponsor: Eisai Inc.

Target Recruit Count: 32

Registration Number: NCT00659958

Locations: 🇪🇸
Complejo Hospitalario de Pontevedra, Pontevedra, Galicia, Spain
🇪🇸
Complejo Hospitalario Universitario 'Juan Canalejo', Coruna, Galicia, Spain
🇪🇸
Centro Sanitario Complexo Hospitalario "XERAL-CALDE", Lugo, Galicia, Spain

and more 8 locations

Zonisamide in the Treatment of Essential Tremor

Not Applicable

Terminated

Conditions: Essential Tremor

Interventions: Drug: Zonisamide

First Posted Date: 2008-02-15

Last Posted Date: 2014-07-17

Lead Sponsor: Loma Linda University

Target Recruit Count: 9

Registration Number: NCT00616343

Zonisamide vs. Placebo in the Treatment of Alcohol Dependence

Phase 4

Completed

Conditions: Alcoholism
Alcohol Abuse
Alcohol Dependence

Interventions: Drug: Placebo
Drug: zonisamide

First Posted Date: 2008-01-16

Last Posted Date: 2010-10-15

Lead Sponsor: UConn Health

Target Recruit Count: 40

Registration Number: NCT00595556

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States

Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)

Phase 3

Completed

Conditions: Epilepsy; Paediatric Partial Onset Seizures

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2007-12-03

Last Posted Date: 2013-05-13

Lead Sponsor: Eisai Inc.

Target Recruit Count: 207

Registration Number: NCT00566254

A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Carbamazepine
Drug: Zonisamide

First Posted Date: 2007-05-23

Last Posted Date: 2015-12-24

Lead Sponsor: Eisai Inc.

Target Recruit Count: 583

Registration Number: NCT00477295

The Effects of Zonisamide on Alcohol Dependence

Phase 2

Completed

Conditions: Alcoholism

Interventions: Drug: Zonisamide

First Posted Date: 2006-12-04

Last Posted Date: 2010-05-11

Lead Sponsor: Boston University

Target Recruit Count: 16

Registration Number: NCT00406692

Locations: 🇺🇸
Boston University School of Medicine, Boston, Massachusetts, United States

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorders

Interventions: Drug: olanzapine
Behavioral: Wellness education
Drug: amantadine
Drug: metformin
Drug: zonisamide

First Posted Date: 2006-11-22

Last Posted Date: 2009-10-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 199

Registration Number: NCT00401973

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation

Alcohol Self Administration Laboratory

Not Applicable

Completed

Conditions: Alcoholism

Interventions: Drug: zonisamide
Drug: Placebo

First Posted Date: 2006-11-14

Last Posted Date: 2017-07-14

Lead Sponsor: Boston University

Target Recruit Count: 10

Registration Number: NCT00398918

Locations: 🇺🇸
Boston University Medical Campus, Boston, Massachusetts, United States

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Phase 3

Completed

Conditions: Weight Gain

Interventions: Drug: Zonisamide
Drug: olanzapine
Drug: Sugar Pill (placebo)

First Posted Date: 2006-08-15

Last Posted Date: 2012-04-13

Lead Sponsor: Lindner Center of HOPE

Target Recruit Count: 42

Registration Number: NCT00363376

Locations: 🇺🇸
The Lindner Center of HOPE, Mason, Ohio, United States

Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures

Phase 3

Completed

Conditions: Partial Seizures

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2006-05-18

Last Posted Date: 2014-08-15

Lead Sponsor: Eisai Inc.

Target Recruit Count: 240

Registration Number: NCT00327717

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy